Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-24-000338
Filing Date
2024-06-14
Accepted
2024-06-14 16:18:00
Documents
1
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 5483
  Complete submission text file 0001610717-24-000338.txt   7013
Mailing Address C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
Ho Maykin (Reporting) CIK: 0001646395 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41802 | Film No.: 241045068

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Issuer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)